A Boston jury ruled today that Roche’s new drug, Mircera, infringed 11 Amgen patent claims - a very big deal for the Thousand Oaks-based biotech/drug firm. For now, the jury verdict will block Roche from introducing an anemia drug in the U.S., though the company said it was looking at all legal options, including an appeal. Amgen's two anemia drugs, Epogen and Aranesp, had sales last year of $6.6 billion last year - nearly half the company’s total. Amgen said it would seek an injunction to prevent Roche from releasing Mircera in the U.S. Amgen shares were up 2.8 percent today. (NYT)
More by Mark Lacter:
American-US Air settlement with DOJ includes small tweak at LAXSocal housing market going nowhere fast
Amazon keeps pushing for faster L.A. delivery
Another rugged quarter for Tribune Co. papers
How does Stanford compete with the big boys?
Those awful infographics that promise to explain and only distort
Best to low-ball today's employment report
Further fallout from airport shootings
Crazy opening for Twitter*
Should Twitter be valued at $18 billion?
Recent stories:
Letter from Down Under: Welcome to the HomogenoceneOne last Florida photo
Signs of Saturday: No refund
'I Am Woman,' hear them roar
Bobcat crossing
New at LA Observed
On the Politics Page
Go to Politics
Sign up for daily email from LA Observed